

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **POSITIVE PROFIT ALERT**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the year ended December 31, 2019, it is expected that the profit attributable to equity shareholders of the Company for year ended December 31, 2019 will increase more than 58% compared with the profit attributable to equity shareholders of the Company for the year ended December 31, 2018. Such increase was primarily attributable to: (i) leading technology platform, best-in-industry timeline and excellent execution track record contributing to more market share and new integrated projects being added to our pipeline; (ii) the Group’s innovative proprietary technology platforms, including but not limited to the bispecific antibody technology platform WuXiBody™, have been steadily adopted in the industry; (iii) strong growth in revenue, including milestone revenue generated from WuXiBody™ platform, as well as milestone revenue generated from projects progressed along the value chain, as a result of the success of the Group’s “Follow-the-Molecule” strategy; and (iv) improvement of operational efficiency, which were partially offset by the ramp-up of new sites, and by the increase of administrative expenses in line with the Group’s business growth.

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2019. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2019, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the annual results announcement of the Group for the year ended December 31, 2019, which is expected to be published by the end of March 2020.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, March 4, 2020

*As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.*

\* *For identification purpose only*